SIGA Profile
SIGA Technologies, Inc., a publicly-traded pharmaceutical firm, specializes in addressing health security and infectious disease challenges within the United States. Established in 1995 and based in New York City, SIGA Technologies focuses on developing and commercializing innovative therapies. Its flagship product, TPOXX, is an oral antiviral medication designed to combat human smallpox caused by the variola virus.
The company's strategic collaboration with Cipla Therapeutics underscores its commitment to advancing antibacterial drugs, particularly targeting biothreats. This partnership enhances SIGA Technologies' capability to deliver sustained innovation and broaden access to critical medical solutions. With a dedicated focus on biodefense and public health preparedness, SIGA Technologies remains at the forefront of developing essential treatments to protect against infectious diseases.
Beyond its core product portfolio, SIGA Technologies actively engages in research and development initiatives aimed at expanding its therapeutic offerings. The company's efforts extend to enhancing global health resilience through strategic partnerships and collaborations. Through its continued innovation and commitment to advancing medical countermeasures, SIGA Technologies reinforces its position as a pivotal player in the pharmaceutical landscape.
Incorporating cutting-edge technologies and leveraging its extensive expertise, SIGA Technologies is dedicated to addressing emerging infectious disease threats and contributing to national and international health security efforts. The company's steadfast mission underscores its role in safeguarding public health and fostering resilience against biological threats worldwide.
|
